Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study
In unresectable HCC, adding PD-1 blockade to SBRT enhances anti-tumor activity and improves long-term survival outcomes.
Authors
- Tianfu Wen
- Hong Shi (ORCID: https://orcid.org/0000-0002-0182-8729)
- Xubiao Wei
- Shuqun Cheng
- Zhaochong Zeng
- Y. J. Jiang (ORCID: https://orcid.org/0009-0003-4192-5253)
- Miaomiao Wang
- Weixing Guo
- Yong Li
- Yang Jiao
- Jie Shi
Institutions
- Second Military Medical University (CN)
- Sichuan University (CN)
- Fudan University (CN)
- Soochow University (CN)
- West China Hospital of Sichuan University (CN)
- Zhongshan Hospital (CN)
- Shanghai Pulmonary Hospital (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1093/oncolo/oyaf437
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00